Palvella Therapeutics (NASDAQ:PVLA) Shares Gap Up on Analyst Upgrade

Shares of Palvella Therapeutics, Inc. (NASDAQ:PVLA) gapped up prior to trading on Thursday after Mizuho raised their price target on the stock from $205.00 to $250.00. The stock had previously closed at $128.60, but opened at $140.28. Mizuho currently has an outperform rating on the stock. Palvella Therapeutics shares last traded at $142.63, with a volume of 220,474 shares trading hands.

Several other analysts also recently commented on PVLA. Truist Financial set a $210.00 price objective on Palvella Therapeutics in a research note on Tuesday. Cantor Fitzgerald raised their target price on shares of Palvella Therapeutics from $120.00 to $200.00 and gave the company an “overweight” rating in a research report on Thursday, November 6th. Chardan Capital boosted their price target on Palvella Therapeutics from $174.00 to $210.00 and gave the stock a “buy” rating in a research report on Tuesday. Craig Hallum began coverage on shares of Palvella Therapeutics in a research note on Thursday, December 4th. They set a “buy” rating and a $175.00 price objective on the stock. Finally, BTIG Research increased their price target on Palvella Therapeutics from $192.00 to $215.00 and gave the company a “buy” rating in a research note on Wednesday. Two analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Palvella Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $176.44.

Insider Buying and Selling at Palvella Therapeutics

In other news, COO Kathleen Goin sold 4,302 shares of the firm’s stock in a transaction that occurred on Wednesday, January 21st. The shares were sold at an average price of $97.63, for a total value of $420,004.26. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders own 20.50% of the company’s stock.

Key Stories Impacting Palvella Therapeutics

Here are the key news stories impacting Palvella Therapeutics this week:

• Positive Sentiment: HC Wainwright raised its price target to $255 and materially boosted multi‑year EPS forecasts, reiterating a Buy rating — a strong analyst endorsement that can support higher valuation expectations. HC Wainwright Price Target/Upgrade
• Positive Sentiment: Chardan Capital also lifted its price target to $210, adding to a cluster of bullish analyst views and a high median street target (~$200) that can underpin demand for the stock. Chardan Price Target
• Positive Sentiment: The company successfully priced an upsized public offering of 1.6M shares at $125 per share (with a 30‑day option for an additional 240k shares), expected to generate approx. $200M in gross proceeds to fund development of QTORIN programs — a meaningful cash runway for a clinical‑stage biotech. Offering Pricing (GlobeNewswire)
• Neutral Sentiment: Some reports note the stock hit a multi‑year high in intraday trade following the upsized offering — showing demand and market interest, but not necessarily a durable trend. Investing.com Article
• Negative Sentiment: All shares in the offering are being sold by Palvella (company‑issued), which will dilute existing holders and can pressure the stock as the new supply hits the market. The offering’s dilutive effect likely contributed to downward pressure despite the cash infusion. Quiver Quant Offering Summary
• Negative Sentiment: Short interest rose ~22% in February to ~1.67M shares (≈17.8% of float), increasing potential selling pressure and volatility (days‑to‑cover ~5.5). Combined with recent insider selling, these are headwinds for the share price. (internal data)

Institutional Investors Weigh In On Palvella Therapeutics

Institutional investors have recently made changes to their positions in the stock. Millennium Management LLC bought a new stake in shares of Palvella Therapeutics in the 1st quarter valued at $7,553,000. Goldman Sachs Group Inc. bought a new stake in shares of Palvella Therapeutics during the first quarter valued at approximately $533,000. Geode Capital Management LLC raised its holdings in Palvella Therapeutics by 84.7% during the second quarter. Geode Capital Management LLC now owns 173,986 shares of the company’s stock worth $3,923,000 after buying an additional 79,787 shares during the last quarter. Police & Firemen s Retirement System of New Jersey bought a new position in Palvella Therapeutics in the 2nd quarter valued at about $37,000. Finally, JPMorgan Chase & Co. lifted its holdings in shares of Palvella Therapeutics by 108,066.7% in the second quarter. JPMorgan Chase & Co. now owns 3,245 shares of the company’s stock valued at $73,000 after purchasing an additional 3,242 shares in the last quarter. Institutional investors own 40.11% of the company’s stock.

Palvella Therapeutics Trading Down 9.0%

The stock has a market capitalization of $1.60 billion, a PE ratio of -51.34 and a beta of -0.16. The stock’s fifty day simple moving average is $94.53 and its 200-day simple moving average is $79.99.

Palvella Therapeutics Company Profile

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.